• Technology and Data
  • Front End Sales and Marketing
  • Allergy
  • HIV
  • Women's Health
  • Migraine
  • Compounding
  • Continuous Glucose Monitoring
  • Mental Health Awareness
  • Veterinary Pharmacy
  • CBD
  • Infectious Disease
  • Eye Health
  • Digestive Health
  • Biosimilars
  • Influenza
  • Shingles
  • COPD Management
  • Pediatrics
  • Generics
  • Pain Management
  • COVID-19
  • Immunization
  • Oncology
  • Anticoagulants
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Respiratory
  • Heart Health
  • Cardiovascular Clinical Consult

Improvements made to hemophilia B therapy


Wyeth Pharmaceuticals has announced the FDA approval of BeneFIX R2 Kit

Wyeth Pharmaceuticals has announced the FDA approval of BeneFIX R2 Kit, an updated version of the currently available product BeneFIX Coagulation Factor IX (recombinant). Four enhancements have been made, including a 2,000 IU dosage vial, a needleless reconstitution device, a prefilled diluent syringe, and a reduced diluent volume. According the manufacturer, the lower diluent volume and the prefilled syringe will allow for easier product preparation. The BeneFIX R2 Kit is indicated for the control and prevention of hemorrhagic episodes including control and prevention in surgical settings in patients with hemophilia B, also known as congenital factor IX deficiency or Christmas disease. Wyeth expects the new product to be available in mid-2007.

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.

Related Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
© 2023 MJH Life Sciences

All rights reserved.